FDA Announces Change in Status of 12 Peptides SSRP Institute FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of Regeneration or Risk? A Narrative Review of BPC 157 for Musculoskeletal Healing Current Reviews in Musculoskeletal Medicine Springer Nature Link Major peptide regulatory news this week. The FDA announced on April 15 that it will remove 12 peptides from Category 2 of the 503A bulk drug substances list after seven calendar days.